Key Challenges Significant demand puts pressure on supply chain Ready-to-Use (RTU) primary packaging availability is critical to ensure clinical supplies and scale-up Mitigate risks from development to commercial Time to market is a key variable to seize the opportunity Minimize drug product wastage Fixed vs variable dose - single or multiple injections To follow patient preferences across geographies, both pens and auto-injectors are viable GLP-1 wide Stevanato Group is the right partner for GLP-1 & Peptides through our integrated offering Stevanato Group can serve GLP-1 & Peptides production processes with comprehensive solutions covering the full pharma value chain
Generally, liquid formulations are administered at a dose volume of 25150 L, with an upper limit of 200 L [25]
The SUPRPASS-4 trial (262), involving 2002 participants with high-risk cardiovascular profiles followed for up to 104 weeks, showed no difference in 4-MACE events (cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina) with tirzepatide compared to insulin glargine (HR 0.74
Lee JH, Kim Y, Choi JW, Kim YS
